Qlaris Bio has reported positive topline outcomes from two randomised Phase II US trials, Osprey and Apteryx, of QLS 111 in individuals with primary open-angle glaucoma (POAG) and ocular ...
The drug in question, dubbed QLS‑111, has been created with Qlaris’ ATP-sensitive potassium channel modulator platform and is designed to lower intraocular pressure (IOP). The results ...
QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass., February 05, 2025--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback